Soligenix Inc SNGX

NAS: SNGX | ISIN: US8342233074   31/05/2024
0,315 USD (-10,00%)
(-10,00%)   31/05/2024

31 mei 2024 · Soligenix Announces Reverse Stock Split · Persbericht

29 mei 2024 · Soligenix Encourages Stockholders to Vote their Shares at the Annual Meeting · Persbericht

24 mei 2024 · Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting · Persbericht

23 mei 2024 · Soligenix Encourages Stockholders to Vote "FOR" Reverse Stock Split · Persbericht

21 mei 2024 · SuVax™ and MarVax™ Thermostable Vaccine Platform to be Presented at the Vaccine Technology IX Conference · Persbericht

20 mei 2024 · Soligenix Encourages Stockholders to Vote Prior to Annual Meeting · Persbericht

16 mei 2024 · Positive Clinical Results from HyBryte™ Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma Published in JEADV Clinical Practice · Persbericht

10 mei 2024 · Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial Results · Persbericht

6 mei 2024 · Soligenix to Present at Upcoming Conferences · Persbericht

25 april 2024 · Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa · Persbericht

18 april 2024 · Soligenix Announces Pricing of $4.75 Million Public Offering · Persbericht

15 april 2024 · FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection · Persbericht

11 april 2024 · FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection · Persbericht

3 april 2024 · Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency · Persbericht

15 maart 2024 · Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results · Persbericht

8 februari 2024 · Soligenix Announces Formation of Behçet's Disease Medical Advisory Board · Persbericht

25 januari 2024 · Soligenix to Present at The Microcap Conference · Persbericht

8 januari 2024 · FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease · Persbericht

4 januari 2024 · Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis · Persbericht

2 januari 2024 · Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses · Persbericht

Mijn selecties